MedDataX Logo

Expression of Erythroid Differentiation Regulator 1 (Erdr1) in Vitiligo

NCT ID: NCT03377998

Last Updated: 2017-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-31

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Expression of Erythroid differentiation regulator 1 (Erdr1) cytokine in vitiligo

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erythroid Differentiation Regulator 1 (Erdr1) Cytokine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitiligo patients

lesional skin biopsy to measure ERDR1 level

Group Type EXPERIMENTAL

skin biopsy

Intervention Type OTHER

Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.

controls

normal skin biopsy to measure ERDR1 level

Group Type EXPERIMENTAL

skin biopsy

Intervention Type OTHER

Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

skin biopsy

Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with generalized non-segmental vitiligo.
* Both sexes.
* Age \>18 years old.
* New cases or cases not receiving any medication for at least 3 months ago.

Exclusion Criteria

* Segmental or Universal vitiligo
* Autoimmune diseases
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maha Fathy Elmasry

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maha Elmasry, MD

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maha Fathy Elmasry, MD

Role: CONTACT

Phone: 00201222633740

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dermatology 4

Identifier Type: -

Identifier Source: org_study_id